A new antibody called MQI‑201 is being developed as a potential treatment for advanced solid cancers that respond poorly to existing immunotherapies, such as certain types of prostate cancer, pancreatic cancer, and sarcomas. These tumors are often called “cold” because they have little immune cell infiltration and usually do not benefit from checkpoint inhibitors or […]
A new type of cancer treatment called Bvax is drawing attention in prostate cancer because it may be able to reach inside tumors that are hard to treat with standard immunotherapies. Bvax is made from a patient’s own B cells, which are activated and loaded with tumor‑related proteins, then given back to the body. Once […]
ASTX295 is an experimental cancer drug that works by turning on a powerful tumor‑suppressor protein called p53 in cancer cells that still have a normal version of the gene TP53. In many cancers, p53 is not broken but is kept switched off by another protein called MDM2, which constantly tags p53 for destruction. ASTX295 blocks […]
We know that exercise can help reduce the risk of getting prostate cancer and may slow its progression, but exactly how this happens inside the body has remained unclear. A recent study in mice has now uncovered an important new mechanism that links physical exercise to the way tumors behave and how the immune system […]
In advanced prostate cancer, castration‑resistant and neuroendocrine variants present some of the toughest clinical challenges because they often lose dependence on androgen receptor signaling and become refractory to hormone‑targeted therapies. Within this resistant landscape, MUC1‑C, the C‑terminal subunit of the mucin‑1 oncoprotein, emerges as a promising alternative target. MUC1‑C is aberrantly overexpressed and under‑glycosylated in […]
Researchers have developed a new targeted therapy for advanced prostate cancer called JZY‑2233, a degrader‑antibody conjugate that homes in on prostate‑specific membrane antigen (PSMA) while delivering a highly potent CBP/p300 degrader directly to tumor cells. CBP and p300 are transcriptional coactivators that help the androgen receptor drive oncogenic gene programs in prostate cancer, and small‑molecule […]
A promising new experimental drug called NEOK001 (also known as ABL206) is emerging as a potential therapy for advanced cancers that express two specific proteins on their surface: B7‑H3 and ROR1. Among these cancers, prostate cancer is one of the tumor types where early data already show signs of activity, making NEOK001 a candidate of […]
JMKX007129 is a new small‑molecule drug that targets the N‑terminal domain (NTD) of the androgen receptor (AR) in prostate cancer. It is designed to overcome resistance seen with current AR‑ligand binding domain (LBD) inhibitors, which often stop working in castration‑resistant prostate cancer (CRPC) when AR develops mutations or produces splice variants like AR‑V7. JMKX007129 builds […]
AUTOTACs (Autophagy‑Targeting Chimeras), are molecules designed to force cancer cells to “clean up” and destroy the androgen receptor (AR), a key driver of prostate cancer growth and progression. The latest research on two second‑generation AR‑targeting AUTOTACs, ATB‑238 and ATB‑239, shows that these compounds can effectively degrade not only the normal AR but also its troublesome […]
RAX104 is a small molecule ligand designed specifically to target PSMA, the protein that is highly expressed on the surface of prostate cancer cells. When labeled with ²²⁵Ac, it forms a radioligand that combines the physical advantages of actinium‑225 (high linear energy transfer and a 10‑day half‑life) with a ligand engineered for better tumor retention. […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy